Compounded semaglutide sits in one of the most misunderstood corners of U.S. drug law. Depending on whose article you read, it's "illegal," "a gray area," or "the same as Wegovy for a fraction of the price." None of those framings are quite right. This guide walks through exactly how compounding law works in 2026, what changed when the FDA resolved the semaglutide shortage, and how to confirm your telehealth provider is using a legitimate pharmacy.
What is compounded semaglutide?
Compounded semaglutide is a medication prepared by a licensed pharmacy that contains semaglutide — the same active ingredient used in Ozempic and Wegovy — in a customized formulation. Most compounded versions are injectable solutions combined with a secondary ingredient such as cyanocobalamin (vitamin B12), niacinamide, or pyridoxine. The combination creates a patient-specific formulation that commercial Ozempic and Wegovy don't offer.
It's not a generic. Generics are FDA-approved copies of a brand drug that go through the ANDA process. Compounded medications are an entirely different regulatory pathway authorized under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
The FDA's stance: 503A and 503B pharmacies
Compounding in the U.S. is governed by two sections of federal law, each creating a distinct class of pharmacy.
503A pharmacies
503A compounding pharmacies are state-licensed and regulated primarily by state boards of pharmacy, with some FDA oversight. They compound medications pursuant to a valid prescription for an individual, identified patient. They cannot produce large anticipatory batches, and they cannot ship to states where they aren't licensed (though most hold licenses in 45+ states). The overwhelming majority of compounded semaglutide dispensed through telehealth in 2026 comes from 503A pharmacies.
503B outsourcing facilities
503B outsourcing facilities are federally registered with the FDA and inspected to current Good Manufacturing Practice (cGMP) standards similar to traditional drug manufacturers. They can compound in larger batches without patient-specific prescriptions and ship to healthcare facilities or, in some arrangements, direct to patients. 503B facilities faced tighter restrictions on semaglutide once the drug left the shortage list.
Both types are legal, and both produce medications that are not FDA-approved as finished products — that's a feature of compounding, not a bug. The FDA's own human drug compounding page lays out this framework in detail.
Why compounded semaglutide is still available after the shortage ended
In early 2025, the FDA declared the semaglutide shortage resolved. Under 503B rules, outsourcing facilities could no longer produce bulk compounded semaglutide on shortage grounds alone. A wave of headlines declared compounded semaglutide "dead."
It wasn't. Here's what actually happened:
- 503A continued under patient-specific rules. 503A pharmacies can compound for individual patients when the prescriber documents a clinical reason the commercial product doesn't meet the patient's needs — for example, a customized dose, an allergy to an inactive ingredient, or a combination formulation with B12.
- Litigation during 2025 preserved access. Legal challenges brought by compounding industry associations slowed and narrowed enforcement, and court rulings carved out continued 503A access while the broader rulemaking continues.
- Telehealth providers adapted. Most legitimate telehealth platforms shifted to semaglutide-plus-B12 or similar combination formulations dispensed exclusively through 503A pharmacies with patient-specific prescriptions.
Net effect: compounded semaglutide remains legal and widely available in 2026, but the supply chain is concentrated in 503A pharmacies operating under patient-specific prescription requirements.
Tirzepatide shortage status
Tirzepatide's path diverged. The FDA's shortage resolution for tirzepatide was finalized in late 2024 after litigation, and 503B facilities stopped bulk compounding. 503A patient-specific compounding of tirzepatide continues under the same framework as semaglutide. Providers like MyStart specialize in compounded tirzepatide via 503A partnerships.
How to verify your pharmacy is legitimate
This is the single most important thing a patient can do. Before paying for compounded semaglutide, confirm:
- The pharmacy has a name and a state license. Your telehealth provider should name the specific pharmacy. Look it up on that state's board of pharmacy license verification portal. Every state has one and it's free to search.
- PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB), operated by the Accreditation Commission for Health Care, accredits compounding pharmacies that pass rigorous quality audits. Search PCAB's directory for your pharmacy's name.
- FDA 503B registration (if applicable). If the provider claims 503B sourcing, the facility must appear on the FDA's registered outsourcing facilities list.
- USP 797/800 compliance. These are sterile compounding standards. Reputable pharmacies mention them prominently.
Already vetted for you
Eden uses a PCAB-accredited 503A partner pharmacy. Sprout and MyStart use 503A pharmacies licensed in 48+ states. We verified each before including them in our provider directory.
Read the Eden Review →Red flags to avoid
- No prescription required. Any U.S. seller dispensing semaglutide without a valid prescription from a licensed provider is breaking federal law. Period.
- "Research use only" or "Not for human consumption" labeling. These products are sold to bypass drug regulations and are not manufactured to pharmaceutical standards. Infection, incorrect dosing, and contamination are documented risks.
- Ships from overseas. Imported personal-use semaglutide is illegal and frequently counterfeit. FDA import alerts have flagged semaglutide from multiple overseas sources in 2024-2025.
- Dramatically below-market pricing. Legitimate 503A semaglutide runs $149-$299/month. Anyone offering $40-60 is either operating illegally or selling research-grade peptide.
- Pharmacy won't be named. A legitimate telehealth provider will tell you the exact pharmacy. If they dodge, that's your answer.
- Payment only in cryptocurrency or wire transfer. Legitimate pharmacies accept standard credit cards and HSA/FSA.
Who should (and shouldn't) use compounded semaglutide
Compounded semaglutide is a reasonable choice for patients who are uninsured or whose plan excludes weight-loss medications, can't get prior authorization approved for Wegovy or Zepbound, have a documented clinical need for a customized formulation, and are comfortable with the tradeoff that finished compounds aren't FDA-evaluated.
It's not the right choice for patients who have full insurance coverage for brand-name GLP-1 at a reasonable copay (use the brand), want maximum safety assurance regardless of cost (use the brand), or live in one of the few states where 503A shipping is restricted (check with the provider first).
For patients weighing insurance vs. self-pay, see our full cost comparison. For a step-by-step walkthrough of getting started, see how to get Ozempic online.
Frequently asked questions
Is compounded semaglutide legal in the United States in 2026?
Yes, when produced by a state-licensed 503A compounding pharmacy or FDA-registered 503B facility, dispensed pursuant to a valid prescription, and prescribed for a medical need that meets compounding criteria.
Didn't the FDA remove semaglutide from the shortage list?
Yes, in early 2025. 503B bulk compounding on shortage grounds ended, but 503A pharmacies continue to compound patient-specific prescriptions with documented clinical need, and telehealth providers adapted their formulations accordingly.
What's the difference between 503A and 503B pharmacies?
503A pharmacies are state-licensed and compound per individual prescription. 503B outsourcing facilities are federally registered, cGMP-inspected, and can produce larger batches. Both are legal compounding routes with different oversight.
How do I verify a compounding pharmacy is legitimate?
Look up the state license on the state board of pharmacy website, confirm PCAB accreditation, verify 503B registration on the FDA's list if applicable, and require your telehealth provider to name the specific pharmacy.
Is compounded semaglutide FDA-approved?
No finished compound is FDA-approved — that's true of all legal compounding, not just semaglutide. The active ingredient comes from an FDA-registered source, and the pharmacy must be licensed and inspected, but the finished product doesn't go through new drug approval.
What are the biggest red flags?
No prescription required, "research use only" labeling, ships from overseas, below-market pricing ($40-60/mo), refusal to name the pharmacy, and payment only in cryptocurrency. Any one of these means you're buying an unregulated product.
Can telehealth providers still prescribe compounded semaglutide?
Yes. Legitimate platforms like Eden, Sprout, and MyStart continue to prescribe via 503A partner pharmacies. Confirm the pharmacy name with your provider before paying.
The bottom line
Compounded semaglutide is legal in 2026 when sourced from a licensed 503A or 503B pharmacy, prescribed by a U.S.-licensed clinician, and dispensed pursuant to a valid patient-specific prescription. The regulatory path tightened after the shortage resolution, but reputable telehealth providers adapted, and legitimate access remains broad. The patient's job is to verify the pharmacy — every other decision flows from that.